Please use this identifier to cite or link to this item:
Title: Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival.
Austin Authors: Huang, Qiutong;Jacquelot, Nicolas;Preaudet, Adele;Hediyeh-Zadeh, Soroor;Souza-Fonseca-Guimaraes, Fernando;McKenzie, Andrew N J;Hansbro, Philip M;Davis, Melissa J;Mielke, Lisa A;Putoczki, Tracy L;Belz, Gabrielle T
Affiliation: Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne 3052, Australia
Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, Australia
The University of Queensland Diamantina Institute, 37 Kent Street, Woolloongabba, Brisbane 4102, Australia
Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
Center for Inflammation, Centenary Institute and the School of Life Sciences, University of Technology Sydney, Sydney 2050, Australia
Department of Clinical Pathology, University of Melbourne, Parkville, Melbourne 3010, Australia
Olivia Newton-John Cancer Research Institute
La Trobe University School of Cancer Medicine, Heidelberg 3084, Australia
Issue Date: 1-Feb-2021 2021-02-01
Publication information: Cancers 2021; 13(3): 559
Abstract: Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches.
DOI: 10.3390/cancers13030559
ORCID: 0000-0003-0282-1892
Journal: Cancers
PubMed URL: 33535624
ISSN: 2072-6694
Type: Journal Article
Subjects: IL-13
colitis-associated cancer
colon cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.